Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis

Malalur, Pannaga; Agastya, Manas; Wahi‐Gururaj, Sandhya; Cross, Chad L.; Deauna‐Limayo, Delva; Kingsley, Edwin C.

doi:10.1002/cam4.3698

Cited by 8 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer survivors will strengthen primary tumor monitoring, leading to earlier detection of a second primary tumor 22 . Additionally, cancer survivors might make lifestyle changes after diagnosis or treatment to have a healthier lifestyle 23 . A healthy lifestyle can reduce the risk of recurrence, secondary primary tumors, and chronic cardiovascular disease in these cancer survivors 24 , 25 .…”

Section: Discussionmentioning

confidence: 99%

Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study

Wang

Chen

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Thyroid cancer patients have a good prognosis, and their long survival increases the likelihood of developing a second primary tumor. Meanwhile, pancreatic cancer (PC) has a poor prognosis and therapeutic efficacy. However, the association between prior thyroid cancer and the subsequent PC prognosis is unknown. Herein, we selected pathologically diagnosed PC patients older than 17 between 2010 and 2015 from the SEER database. We used propensity score matching (PSM) to reduce confounding factors between groups and matched each PC patient with a history of thyroid cancer with 10 PC patients without a history of thyroid cancer. Finally, we selected 103 PC patients with prior thyroid cancer and 1030 PC patients without prior thyroid cancer. Then, we analyzed the factors influencing the overall survival (OS) and the cancer-specific survival (CSS) of PC patients. The median overall survival of PC patients with and without a history of thyroid cancer was 12 and 9 months, respectively. The history of thyroid cancer in PC patients reduced the PC-specific mortality (p < 0.05). Prior thyroid cancer might be a favorable prognostic factor for PC-specific mortality in PC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study

Wang

Chen

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Changes in dietary patterns after the first primary cancer may also lead to better survival with the second primary cancer. Cancer patients tend to have good eating habits after being diagnosed, such as reducing alcohol consumption 26 . Previous studies speculated that a history of alcohol consumption may be a potential prognostic factor for liver cancer patients 27 , 28 .…”

Section: Discussionmentioning

confidence: 99%

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Liu

Heng

Tian

et al. 2022

Sci Rep

View full text Add to dashboard Cite

To explore the effect of prior thyroid cancer on the survival of primary liver cancer (PLC). Eligible PLC patients were selected from the Surveillance, Epidemiology, and End Results (SEER) database during 2004–2016. Propensity score matching (PSM) was used to create a highly comparable control group that PLC patients without prior thyroid cancer. All PLC patients were divided into three groups based on the survival information: (1) PLC-specific death; (2) death due to other causes; (3) alive. The effect sizes were presented by the corresponding hazard ratio (HR) and 95% confidence intervals (CI). Totally, 142 PLC patients with prior thyroid cancer and 1420 PLC patients without prior thyroid cancer were included. During the follow-up period, 714 (45.71%) PLC patients died of liver cancer while 638 (40.85%) PLC patients were alive. Median survival time for PLC patients was 11.00 months, respectively. PLC patients with prior thyroid cancer have a lower risk of death (HR = 0.64; 95% CI: 0.48–0.86). Subgroup analyses stratified by gender displayed the similar relation in female patients with PLC. Prior thyroid cancer may be a protective factor for liver cancer death in PLC patients, especially in female patients.

show abstract

“…After being diagnosed with a hematologic malignancy, patients are in a ‘teachable moment’ [ 28 ]. Clinicians should thus take advantage of this moment and educate patients about the advantages of adopting healthier behaviors.…”

Section: Discussionmentioning

confidence: 99%

“…Clinicians should thus take advantage of this moment and educate patients about the advantages of adopting healthier behaviors. Since advances in cancer treatments increase the prevalence of cancer survivors, this education may be crucial in reducing the risk of secondary malignancies or the risk of developing chronic comorbidities [ 28 ]. If we consider exercise as a drug, researchers should investigate the appropriate dosage in terms of frequency, modalities, intensity, and duration according to cancer stage and treatment, and rehabilitation professionals should give patients precise recommendations in terms of the exercise needed to achieve specific health outcomes.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic education and physical activity are feasible and safe in hematologic cancer patients referred to chemotherapy: results of a randomized controlled trial

Accogli

Denti

Costi

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose Although over 60% of patients with hematologic cancer report distressing fatigue, they often do not receive recommendations on fatigue management strategies. The aim of this pilot study was to estimate the feasibility of therapeutic education and physical activity (TEPA) by measuring the patients’ adherence to this multidimensional intervention. The secondary aim was to estimate the impact of TEPA on clinical outcomes. Methods Patients with hematologic cancer participated in this single-center, open-label, randomized controlled trial. The control group (CG) received two educational group sessions on fatigue and physical activity. The experimental group (EG) received the two educational sessions plus six weekly individual sessions aimed at implementing a personalized physical exercise program. Follow-ups were at 1, 3, and 7 months. Results Forty-six patients referred to chemotherapy were included, corresponding to 54% of recruitment rate. Adherence reached 90% in the EG and 68% in the CG. Most patients (65% in EG and 64% in CG) attended a minimum of 80% of the planned sessions. Overall retention rate was 87% (85% in EG and 91% in CG). No adverse events were registered. No between-group differences were detected in fatigue (FACIT-F), psychological distress (NCCN Distress Thermometer), QoL (EORTC QLQ-C30), or functional exercise capacity (TUG test and 6MWT). Adherence to an active lifestyle, measured by a semi-structured interview, increased from 56.5 to 84% in the EG at 7 months (p = 0.02), whereas it decreased slightly in the CG (from 47.8 to 42.9%). Conclusion Multidimensional rehabilitation interventions are feasible and safe in this population, and larger trials should focus on the efficacy of such approaches on clinically relevant outcomes. Trial registration ClinicalTrials.gov Identifier: NCT03403075.

show abstract

Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 8 publications

References 21 publications

Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study

Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database

Therapeutic education and physical activity are feasible and safe in hematologic cancer patients referred to chemotherapy: results of a randomized controlled trial

Contact Info

Product

Resources

About